Proteostasis Therapeutics Inc (NASDAQ: PTI) went skyward Tuesday, after the company disclosed 'positive' PTI-428 data with statistical significance.
A news release out Monday from the Cambridge, Mass.-based company announced positive study results across all three of the company’s CF pipeline programs. These include a study in CF subjects for PTI-428, a cystic fibrosis transmembrane conductance regulator (CFTR) amplifier; interim data for a study in CF subjects for PTI-801, a new generation CFTR corrector; and studies in healthy volunteers for PTI-808, a CFTR potentiator, and the combination of PTI-428, PTI-801 and PTI-808.
The results support the goal of studying the Company’s novel CFTR modulators in doublet and triplet combinations in CF subjects.
Dr. Patrick Flume, one of the investigators behind the CFTR probe, said "This is an important first step towards translating the scientific potential of the first and only genotype agnostic CFTR modulator in development, and its ability to enhance Orkambi by selectively increasing the production of the CFTR protein.
"I look forward to seeing PTI-428 evaluated in further combination studies, with the goal of fully elucidating the potential of this unique CFTR amplifier."
The 28-day study continues to confirm the safety profile of PTI-428 in that it was generally well tolerated and lacked clinically meaningful drug-drug interactions with ivacaftor and lumacaftor. In all, 14 of 20 subjects receiving PTI-428 and two of four subjects receiving placebo experienced at least one treatment emergent adverse event. There were no serious adverse events.
Proteostasis shares skyrocketed $4.02, or 171.1%, to $6.37.
